Preferred Label : Fidasimtamab;
NCIt synonyms : HER2/PD-1 Bi-specific Antibody BH 2950; Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315;
NCIt definition : A recombinant human immunoglobulin G1 (IgG1) bispecific antibody directed against
the human epidermal growth factor receptor 2 (HER2) and the negative immunoregulatory
human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential
immune checkpoint inhibitory and antineoplastic activities. Upon administration, fidasimtamab
simultaneously targets, binds to and inhibits HER2 and PD-1 and their downstream signaling
pathways, and bridges PD-1-expressing T-cells to HER2-expressing tumor cells. This
may inhibit tumor cell proliferation of HER2-overexpressing cells. Inhibition of PD-1-mediated
signaling may restore immune function through the activation of T-cells and T-cell-mediated
immune responses against the HER2-expressing tumor cells. PD-1, a transmembrane protein
in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune
checkpoint that negatively regulates T-cell activation and effector function when
activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it
plays an important role in tumor evasion from host immunity.;
UNII : JXN644CQ6P;
CAS number : 2377419-89-9;
Molecule name : IBI 315; BH 2950; BH-2950; IBI-315;
NCI Metathesaurus CUI : CL1411981;
Origin ID : C174419;
UMLS CUI : C5667210;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
